A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta) in Patients With Alcoholic Hepatitis
Latest Information Update: 22 Aug 2022
At a glance
- Drugs Pegfilgrastim (Primary) ; Pentoxifylline; Prednisolone
- Indications Alcoholic hepatitis
- Focus Adverse reactions; Therapeutic Use
- 26 Jun 2022 Results assessing the safety and efficacy of pegfilgrastim in patients with alcohol-associated hepatitis, presented at The International Liver Congress 2022.
- 23 Sep 2021 Status changed from recruiting to completed.
- 16 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Aug 2020.